WP 2 - Clinical Science

The primary focus in workpackage 2 will be on the development of a clinical National Center of Excellence for diagnosis and treatment of anaphylaxis and related diseases, and on new treatment modalities (with workpackage 4). Once recruited, the manager will be responsible for the further development of the research program in collaboration with the partners.


WP 2.1 - Predictive values of Component Resolved Diagnostics (CRD) in food allergy will expand ongoing research in the field of identification of specific IgE against specific allergenic proteins in foods (component resolved diagnostics) capable of acting as surrogate parameters for the present gold standard, the double?blind, placebo?controlled food challenge. 


WP 2.2 - Diagnosis of Food Dependent, exercise?induced Anaphylaxis (FDEIA) will address the increasingly common disease Wheat Dependent, Exercise Induced Anaphylaxis where a combination of intake of non?soluble wheat proteins and exercise elicit a severe reaction in athletes and the possible facilitating role of drugs and alcohol on these reactions. These studies will serve as a model and prototype for anaphylactic disease. 


WP 2.3 - Risk of Anaphylaxis in patients with IgE?mediated allergy to penicillin will focus on clinical relevance of IgE antibodies towards penicillin. In other severe anaphylactic reactions to e.g. peanut or wasp the mere presence of specific IgE to the culprit agent does not implicate a mild or severe clinical reaction upon re?exposure, but this is considered the truth with penicillin, according to international guidelines. This statement is poorly documented, however, and we have clinical data supporting that IgE to penicillin does not behave qualitatively different than other types of IgE. 


WP 2.4 - Non-histaminergic angioedema: Identification, characterization and treatment and WP 2.5 - Differential diagnosis: Mastocytosis are focusing on two major differential diagnoses to classical anaphylaxis, angioedema and mastocytosis. In both workpackages large numbers of patients have been/will be investigated and diagnosed in a fixed protocol resulting in data on incidence (workpackage 1), eliciting factors, prognosis, pathophysiology (with inclusion of laboratory experiments from year three in WP 3) and will ultimatively end up with new treatment regimens for both diseases (workpackage 4).

Webdesign af mira.dk